Table 2 Univariate Cox analyses of prognostic factors of survival

Sex

 Female

Ref

Ref

 Male

0.958(0.591–1.553)

0.861

0.904(0.543–1.504)

0.697

Age at diagnosis

 < 3 y

Ref

Ref

 ≥ 3 y

1.081(0.568–2.056)

0.813

0.817(0.435–1.534)

0.529

Histology

 Non-large cell/anaplastic

Ref

Ref

 Large cell/anaplastic

2.097(0.762–5.776)

0.152

2.895(1.039–8.072)

0.042

Molecular grouping

 WNT

Ref

Ref

 SHH

1.961(0.434–8.851)

0.381

1.344(0.285–6.334)

0.709

 Non WNT/SHH

1.497(0.351–6.387)

0.586

1.145(0.263–4.983)

0.857

M stage at diagnosis

 M0

Ref

Ref

 M+

1.322(0.774–2.258)

0.308

1.905(1.014–3.576)

0.045

Chemotherapy before RT

 No

Ref

Ref

 Yes

1.179(0.675–2.057)

0.563

1.169(0.645–2.118)

0.606

Residual disease site before RT

 Brain

Ref

Ref

 Spinal cord

1.036(0.474–2.263)

0.929

1.321(0.556–3.136)

0.528

 Borth

2.180(1.245–3.819)

0.006

2.904(1.528–5.520)

0.001

Concurrent chemotherapy

 No

Ref

Ref

 Yes

0.787(0.287–2.159)

0.641

0.697(0.218–2.222)

0.541

Radiotherapy mode

 IMRT

Ref

Ref

 TOMO

0.765(0.390–1.169)

0.161

0.688(0.389–1.218)

0.200

CSI dose

 < 36 Gy

Ref

Ref

 ≥ 36 Gy

1.271(0.400-4.045)

0.684

1.271(0.396–4.077)

0.686

Radiotherapy dose

 ≤ 54 Gy

Ref

Ref

 > 54 Gy

1.103(0.346–3.516)

0.868

1.162(0.362–3.734)

0.801

Radiation response

 CR

Ref

Ref

 Non-CR

2.465(1.478–4.110)

0.001

3.773(2.075–6.861)

< 0.001